Patent

SpicyIP Tidbit: Novartis Pursues Aggressive Patent Strategy with Respect to Drug Vildagliptin


According to Times of India, Novartis obtained favourable court orders restraining five Ahmedabad-based pharma companies from manufacturing its patented drug for diabetes, Vildagliptin. Further, citing validity of its patent till 09 December 2019, Novartis moved the commercial court in Vadodara to ensure that four other companies do not get into production of the drug. It is reported that Novartis approached the Court after obtaining the requisite information from the State Government.

Mathews P. George

Mathews P. George

Mathews is a graduate of National University of Juridical Sciences, Kolkata. His interest in intellectual property was kindled when he bagged the second position in his very second year in the prestigious Nani Palkhiwala Essay Competition on Intellectual Property. Winner of almost a dozen essay competitions in his law school days, he was involved in various research and policy initiatives relating to intellectual property. His stint as a student of Prof. Shamnad Basheer further accentuated his interest in intellectual property.

2 comments.

  1. Sadly, No!

    Am I missing something, or is “aggressive patent strategy” being used to mean “enforcing its patent”? Seems a bit much.

    Reply
  2. Freq. Anon.

    Kind of agree with you, Mr. Sadly No.
    However, I believe that the bent was more in the context of patent expiring in 15 months from now … I am sure Novartis is (rightly so) going to not let any non-licensed player before Dec 2019.

    Reply

Leave a Reply

Your email address will not be published.